 Takeda Pharmaceutical Co Ltd NYSSE: TAK has agreed to secure global rights from Ovid Therapeutics Inc NASDAQ: OVID for soticlestat TAK-935OV935 for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome DS and Lennox-Gastaut syndrome LGS. Under this new agreement, Takeda will develop and commercialize soticlestat globally, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement announced in 2017. 